Dyax (DYAX) Stock Research, Analysis & News

Quick Analysis on Dyax (DYAX) Stock as of August 24, 2019

The Stock pays no dividend
Average trading volume is relatively low at 0
(See more information about Dyax (DYAX) Stock below)

Dyax (DYAX) Stock Profile Summary

Dyax Corp., a biopharmaceutical company, engages in the discovery, development, and commercialization of biotherapeutics for unmet medical needs with an emphasis on inflammatory and oncology indications. The company utilizes its proprietary drug discovery technology, known as phage display, to identify antibody, small protein, and peptide compounds for clinical development. It commercializes its lead product candidate, DX-88, a recombinant small protein, under the KALBITOR (ecallantide) name for treatment of acute attacks of hereditary angioedema in patients 16 years of age and older. The company is also developing DX-88 for the reduction of blood loss during surgery in collaboration with Cubist Pharmaceuticals, Inc.; and for the treatment of retinal diseases in collaboration with Fovea Pharmaceuticals SA, as well as for the treatment of angiotensin converting enzyme inhibitor-induced angioedema and other angioedema indications. Its other discovery and development programs include DX-2240, an antibody that targets Tie-1 receptor on tumor blood vessels; and DX-2400 antibody, an inhibitor that inhibits matrix metalloproteinase 14 on tumor cells and tumor blood vessels. In addition, the company provides patent licenses to other biopharmaceutical and pharmaceutical companies to use its phage display patents, to discover and develop biologic compounds for use in specified fields; offers library licenses to use its phage display libraries in connection with their internal therapeutic development programs; and performs funded research for various collaborators. Further, it has co-development collaboration agreements with Athera Biotechnologies AB, Commonwealth Scientific and Industrial Research Organisation, Defiante Farmaceutica, S.A. and Syntonix Pharmaceuticals, Inc. Dyax Corp. was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Dyax (DYAX) Stock Key Statistics Research and Analysis as of August 24, 2019

Dyax (DYAX) Stock Competitor Research and Analysis

ViroPharma Inc. (VPHM)Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)Mylan, Inc. (MYL)
Pfizer Inc. (PFE)Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)Sanofi-Aventis (SNY)
Novartis AG (NVS)AstraZeneca PLC (AZN)
Abbott Laboratories (ABT)Bristol-Myers Squibb Company (BMY)

Mutual Funds with Dyax (DYAX) Stock in its top 10 holdings

FundCategoryDYAX Holding Percentage
PRIMECAP Odyssey Aggressive GrowthMid-Cap Growth4.3%

Latest Market News on Dyax (DYAX)


Click here to find the latest news on Dyax (DYAX)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

ViroPharma Inc. (VPHM)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)
Novartis AG (NVS)
AstraZeneca PLC (AZN)
Abbott Laboratories (ABT)
Bristol-Myers Squibb Company (BMY)